Zacks Research Has Bullish Estimate for BMRN Q1 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at Zacks Research raised their Q1 2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $0.69 for the quarter, up from their prior forecast of $0.61. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $3.30 EPS, Q1 2026 earnings at $0.91 EPS, Q3 2026 earnings at $1.07 EPS, Q4 2026 earnings at $1.16 EPS and FY2026 earnings at $4.12 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Several other research analysts also recently weighed in on BMRN. Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price on the stock in a research note on Monday, February 24th. StockNews.com upgraded BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Monday, March 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $70.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler raised their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an “overweight” rating in a report on Thursday, February 20th. Finally, UBS Group raised their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Trading Up 3.0 %

Shares of BMRN stock opened at $71.55 on Monday. The business’s 50 day moving average is $66.31 and its two-hundred day moving average is $68.51. BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The company has a market capitalization of $13.65 billion, a P/E ratio of 32.52, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Hedge funds have recently bought and sold shares of the stock. LRI Investments LLC increased its position in BioMarin Pharmaceutical by 856.9% during the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after buying an additional 437 shares in the last quarter. TD Private Client Wealth LLC grew its position in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 186 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $36,000. CIBC Private Wealth Group LLC grew its position in shares of BioMarin Pharmaceutical by 64.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 233 shares during the period. Finally, Meeder Asset Management Inc. grew its position in shares of BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 663 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares of the company’s stock, valued at approximately $896,119.90. This trade represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.